EU Industry Renews Call For Digital Regulatory Infrastructure
‘No Further Excuse To Delay’ Says Medicines For Europe
Medicines for Europe has renewed its call for a modern digital regulatory infrastructure in the wake of the COVID-19 pandemic to bolster communication and preparedness for future health crises, insisting that there is “no further excuse to delay.”
You may also be interested in...
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.
While the European off-patent industry has welcomed the latest update to the EU’s industrial strategy, including a detailed analysis of European dependencies on the global API manufacturing network, it has urged the European Commission to go further and provide “tailored actions” to bolster local manufacturing.